Genome-wide DNA methylation profile of leukocytes from melanoma patients with and without CDKN2A mutations

Experimental and Molecular Pathology

Volumn 97, Issue 3, 2014, Pages 425-432

  de Araújo, Érica Sara Souza ^a   Marchi, Fabio Albuquerque ^a,b   Rodrigues, Tatiane Cristina ^b   Vieira, Henrique Cursino ^b   Kuasne, Hellen ^a   Achatz, Maria Isabel Waddington ^a   Moredo, Luciana Facure ^a   de Sá, Bianca Costa Soares ^a   Duprat, João Pereira ^a   Brentani, Helena Paula ^b   Rosenberg, Carla ^b   Carraro, Dirce Maria ^a   Krepischi, Ana Cristina Victorino ^a,b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CDKN2A; DNA methylation; Leukocytes; Melanoma; Melanoma epigenetics

Indexed keywords

CYTIDINE; GUANIDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CARCINOGENESIS; CDKN2A GENE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC PREDISPOSITION; GERMLINE MUTATION; HUMAN; HUMAN CELL; LEUKOCYTE; MELANOMA; MUTATIONAL ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; DNA MICROARRAY; FEMALE; GENETICS; GENOTYPE; MALE; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GERM-LINE MUTATION; HUMANS; LEUKOCYTES; MALE; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84922636122     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.09.009     Document Type: Article

References (51)

1. Amos C.I., Wang L.-E., Lee J.E., Gershenwald J.E., Chen W.V., Fang S., Kosoy R., Zhang M., Qureshi A.a, Vattathil S., Schacherer C.W., Gardner J.M., Wang Y., Bishop D.T., Barrett J.H., MacGregor S., Hayward N.K., Martin N.G., Duffy D.L., Mann G.J., Cust A., Hopper J., Brown K.M., Grimm E.a, Xu Y., Han Y., Jing K., McHugh C., Laurie C.C., Doheny K.F., Pugh E.W., Seldin M.F., Han J., Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum. Mol. Genet. 2011, 20:5012-5023. 10.1093/hmg/ddr415.
2. Barrett J.H., Iles M.M., Harland M., Taylor J.C., Aitken J.F., Andresen P.A., Akslen L.a, Armstrong B.K., Avril M.-F., Azizi E., Bakker B., Bergman W., Bianchi-Scarrà G., Bressac-de Paillerets B., Calista D., Cannon-Albright L.a, Corda E., Cust A.E., Debniak T., Duffy D., Dunning A.M., Easton D.F., Friedman E., Galan P., Ghiorzo P., Giles G.G., Hansson J., Hocevar M., Höiom V., Hopper J.L., Ingvar C., Janssen B., Jenkins M.a, Jönsson G., Kefford R.F., Landi G., Landi M.T., Lang J., Lubiński J., Mackie R., Malvehy J., Martin N.G., Molven A., Montgomery G.W., van Nieuwpoort F.a, Novakovic S., Olsson H., Pastorino L., Puig S., Puig-Butille J.A., Randerson-Moor J., Snowden H., Tuominen R., Van Belle P., van der Stoep N., Whiteman D.C., Zelenika D., Han J., Fang S., Lee J.E., Wei Q., Lathrop G.M., Gillanders E.M., Brown K.M., Goldstein A.M., Kanetsky P.a, Mann G.J., Macgregor S., Elder D.E., Amos C.I., Hayward N.K., Gruis N.a, Demenais F., Bishop J.a N., Bishop D.T. Genome-wide association study identifies three new melanoma susceptibility loci. Nat. Genet. 2011, 43:1108-1113. 10.1038/ng.959.
3. Bishop D.T., Demenais F., Iles M.M., Harland M., Taylor J.C., Corda E., Randerson-Moor J., Aitken J.F., Avril M.-F., Azizi E., Bakker B., Bianchi-Scarrà G., Bressac-de Paillerets B., Calista D., Cannon-Albright L.A., Chin-A-Woeng T., Debniak T., Galore-Haskel G., Ghiorzo P., Gut I., Hansson J., Hocevar M., Höiom V., Hopper J.L., Ingvar C., Kanetsky P.A., Kefford R.F., Landi M.T., Lang J., Lubiński J., Mackie R., Malvehy J., Mann G.J., Martin N.G., Montgomery G.W., van Nieuwpoort F.A., Novakovic S., Olsson H., Puig S., Weiss M., van Workum W., Zelenika D., Brown K.M., Goldstein A.M., Gillanders E.M., Boland A., Galan P., Elder D.E., Gruis N.A., Hayward N.K., Lathrop G.M., Barrett J.H., Bishop J.A.N. Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 2009, 41:920-925. 10.1038/ng.411.
4. Bonasio R., Tu S., Reinberg D. Molecular signals of epigenetic states. Science 2010, 330:612-616. 10.1126/science.1191078.
5. Brown K.M., Macgregor S., Montgomery G.W., Craig D.W., Zhao Z.Z., Iyadurai K., Henders A.K., Homer N., Campbell M.J., Stark M., Thomas S., Schmid H., Holland E.A., Gillanders E.M., Duffy D.L., Maskiell J.A., Jetann J., Ferguson M., Stephan D.A., Cust A.E., Whiteman D., Green A., Olsson H., Puig S., Ghiorzo P., Hansson J., Demenais F., Goldstein A.M., Gruis N.A., Elder D.E., Bishop J.N., Kefford R.F., Giles G.G., Armstrong B.K., Aitken J.F., Hopper J.L., Martin N.G., Trent J.M., Mann G.J., Hayward N.K. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 2008, 40:838-840. 10.1038/ng.163.
6. Chen Y., Soong J., Mohanty S., Xu L., Scott G. The neural guidance receptor Plexin C1 delays melanoma progression. Oncogene 2013, 32:4941-4949. 10.1038/onc.2012.511.
7. Chung H., Lee J., Jeong D., Han I.-O., Oh E.-S. Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression. J. Biol. Chem. 2012, 287:19326-19335. 10.1074/jbc.M111.334730.
8. De Ávila A.L.R., Krepischi A.C.V., Moredo L.F., Aguiar T.F.M., da Silva F.C., de Sá B.C.S., de Nóbrega A.F., Achatz M.I.W., Duprat J.P., Landman G., Carraro D.M. Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma. Fam. Cancer 2014, 10.1007/s10689-014-9736-1.
9. Fargnoli M.C., Gandini S., Peris K., Maisonneuve P., Raimondi S. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur. J. Cancer 2010, 46:1413-1420. 10.1016/j.ejca.2010.01.027.
10. Fedorenko I.V., Gibney G.T., Smalley K.S.M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2013, 32:3009-3018. 10.1038/onc.2012.453.
11. Freedberg D.E., Rigas S.H., Russak J., Gai W., Kaplow M., Osman I., Turner F., Randerson-Moor J.a, Houghton A., Busam K., Timothy Bishop D., Bastian B.C., Newton-Bishop J.a, Polsky D. Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl. Cancer Inst. 2008, 100:784-795. 10.1093/jnci/djn157.
12. Friso S., Udali S., Guarini P., Pellegrini C., Pattini P., Moruzzi S., Girelli D., Pizzolo F., Martinelli N., Corrocher R., Olivieri O., Choi S.-W. Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk. Cancer Epidemiol. Biomarkers Prev. 2013, 22:348-355. 10.1158/1055-9965.EPI-12-0859.
13. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005, 74:481-514. 10.1146/annurev.biochem.74.010904.153721.
14. Hendrix M.J., Seftor E.a, Meltzer P.S., Gardner L.M., Hess a R., Kirschmann D.a, Schatteman G.C., Seftor R.E. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8018-8023. 10.1073/pnas.131209798.
15. Hesson L.B., Hitchins M.P., Ward R.L. Epimutations and cancer predisposition: importance and mechanisms. Curr. Opin. Genet. Dev. 2010, 20:290-298. 10.1016/j.gde.2010.02.005.
16. Hou P., Liu D., Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr. Relat. Cancer 2011, 18:687-697. 10.1530/ERC-11-0212.
17. Hou P., Liu D., Dong J., Xing M. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle. 2012, 11:286-295. 10.4161/cc.11.2.18707.
18. Hyland P.L., Burke L.S., Pfeiffer R.M., Mirabello L., Tucker M.a, Goldstein A.M., Yang X.R. LINE-1 methylation in peripheral blood and the risk of melanoma in melanoma-prone families with and without CDKN2A mutations. Melanoma Res. 2013, 23:55-60. 10.1097/CMR.0b013e32835adc51.
19. Iles M.M., Law M.H., Stacey S.N., Han J., Fang S., Pfeiffer R., Harland M., Macgregor S., Taylor J.C., Aben K.K., Akslen L.a, Avril M.-F., Azizi E., Bakker B., Benediktsdottir K.R., Bergman W., Scarrà G.B., Brown K.M., Calista D., Chaudru V., Fargnoli M.C., Cust A.E., Demenais F., de Waal A.C., Debniak T., Elder D.E., Friedman E., Galan P., Ghiorzo P., Gillanders E.M., Goldstein A.M., Gruis N.a, Hansson J., Helsing P., Hočevar M., Höiom V., Hopper J.L., Ingvar C., Janssen M., Jenkins M.a, Kanetsky P.a, Kiemeney L.a, Lang J., Lathrop G.M., Leachman S., Lee J.E., Lubiński J., Mackie R.M., Mann G.J., Martin N.G., Mayordomo J.I., Molven A., Mulder S., Nagore E., Novaković S., Okamoto I., Olafsson J.H., Olsson H., Pehamberger H., Peris K., Grasa M.P., Planelles D., Puig S., Puig-Butille J.A., Randerson-Moor J., Requena C., Rivoltini L., Rodolfo M., Santinami M., Sigurgeirsson B., Snowden H., Song F., Sulem P., Thorisdottir K., Tuominen R., Van Belle P., van der Stoep N., van Rossum M.M., Wei Q., Wendt J., Zelenika D., Zhang M., Landi M.T., Thorleifsson G., Bishop D.T., Amos C.I., Hayward N.K., Stefansson K., Bishop J.a N., Barrett J.H. A variant in FTO shows association with melanoma risk not due to BMI. Nat. Genet. 2013, 45:428-432. (432e1). 10.1038/ng.2571.
20. Jaffe A.E., Irizarry R.a Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol. 2014, 15:R31. 10.1186/gb-2014-15-2-r31.
21. Koestler D.C., Marsit C.J., Christensen B.C., Accomando W., Langevin S.M. Peripheral Blood Immune Cell Methylation Profiles Are Associated with Nonhematopoietic Cancers. Cancer Epidemiol. Biomarkers Prev. 2012, 21:1293-1302. 10.1158/1055-9965.EPI-12-0361.
22. Lage H., Helmbach H., Grottke C., Dietel M., Schadendorf D. DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett. 2001, 494:54-59.
23. Langevin S.M., Koestler D.C., Christensen B.C., Butler R.a, Wiencke J.K., Nelson H.H., Houseman E.A., Marsit C.J., Kelsey K.T. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. Epigenetics 2012, 7:291-299. 10.4161/epi.7.3.19134.
24. Liang X.S., Pfeiffer R.M., Wheeler W., Maeder D., Burdette L., Yeager M., Chanock S., Tucker M.a, Goldstein A.M., Yang X.R. Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations. Int. J. Cancer 2012, 130:2062-2066. 10.1002/ijc.26231.
25. Ligtenberg M.J.L., Kuiper R.P., Chan T.L., Goossens M., Hebeda K.M., Voorendt M., Lee T.Y.H., Bodmer D., Hoenselaar E., Hendriks-Cornelissen S.J.B., Tsui W.Y., Kong C.K., Brunner H.G., van Kessel A.G., Yuen S.T., van Krieken J.H.J.M., Leung S.Y., Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat. Genet. 2009, 41:112-117. 10.1038/ng.283.
26. Loriot A., De Plaen E., Boon T., De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J. Biol. Chem. 2006, 281:10118-10126. 10.1074/jbc.M510469200.
27. Macgregor S., Montgomery G.W., Liu J.Z., Zhao Z.Z., Henders A.K., Stark M., Schmid H., Holland E.a, Duffy D.L., Zhang M., Painter J.N., Nyholt D.R., Maskiell J.a, Jetann J., Ferguson M., Cust A.E., Jenkins M.a, Whiteman D.C., Olsson H., Puig S., Bianchi-Scarrà G., Hansson J., Demenais F., Landi M.T., Debniak T., Mackie R., Azizi E., Bressac-de Paillerets B., Goldstein A.M., Kanetsky P.a, Gruis N.a, Elder D.E., Newton-Bishop J.a, Bishop D.T., Iles M.M., Helsing P., Amos C.I., Wei Q., Wang L.-E., Lee J.E., Qureshi A.a, Kefford R.F., Giles G.G., Armstrong B.K., Aitken J.F., Han J., Hopper J.L., Trent J.M., Brown K.M., Martin N.G., Mann G.J., Hayward N.K. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 2011, 43:1114-1118. 10.1038/ng.958.
28. Marsit C.J., Koestler D.C., Christensen B.C., Karagas M.R., Houseman E.A., Kelsey K.T. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J. Clin. Oncol. 2011, 29:1133-1139. 10.1200/JCO.2010.31.3577.
29. Paliwal A., Temkin A.M., Kerkel K., Yale A., Yotova I., Drost N., Lax S., Nhan-Chang C.-L., Powell C., Borczuk A., Aviv A., Wapner R., Chen X., Nagy P.L., Schork N., Do C., Torkamani A., Tycko B. Comparative anatomy of chromosomal domains with imprinted and non-imprinted allele-specific DNA methylation. PLoS Genet. 2013, 9:e1003622. 10.1371/journal.pgen.1003622.
30. Pedersen K.S., Bamlet W.R., Oberg A.L., de Andrade M., Matsumoto M.E., Tang H., Thibodeau S.N., Petersen G.M., Wang L. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One 2011, 6:e18223. 10.1371/journal.pone.0018223.
31. Price M.E., Cotton A.M., Lam L.L., Farré P., Emberly E., Brown C.J., Robinson W.P., Kobor M.S. Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin 2013, 6:4. 10.1186/1756-8935-6-4.
32. Prickett T.D., Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin. Cancer Res. 2012, 18:4240-4246. 10.1158/1078-0432.CCR-11-1217.
33. Puntervoll H.E., Yang X.R., Vetti H.H., Bachmann I.M., Avril M.F., Benfodda M., Catricalà C., Dalle S., Duval-Modeste A.B., Ghiorzo P., Grammatico P., Harland M., Hayward N.K., Hu H.-H., Jouary T., Martin-Denavit T., Ozola A., Palmer J.M., Pastorino L., Pjanova D., Soufir N., Steine S.J., Stratigos A.J., Thomas L., Tinat J., Tsao H., Veinalde R., Tucker M.a, Bressac-de Paillerets B., Newton-Bishop J.a, Goldstein A.M., Akslen L.a, Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J. Med. Genet. 2013, 50:264-270. 10.1136/jmedgenet-2012-101455.
34. Reed J.a, Lin Q., Chen D., Mian I.S., Medrano E.E. SKI pathways inducing progression of human melanoma. Cancer Metastasis Rev. 2005, 24:265-272. 10.1007/s10555-005-1576-x.
35. Richards E.J. Inherited epigenetic variation- revisiting soft inheritance. Nat. Rev. Genet. 2006, 7:395-401. 10.1038/nrg1834.
36. Schinke C., Mo Y., Yu Y., Amiri K., Sosman J., Greally J., Verma A. Aberrant DNA methylation in malignant melanoma. Melanoma Res. 2010, 20:253-265. 10.1097/CMR.0b013e328338a35a.
37. Scott G.a, McClelland L.a, Fricke A.F., Fender A. Plexin C1, a receptor for semaphorin 7a, inactivates cofilin and is a potential tumor suppressor for melanoma progression. J. Invest. Dermatol. 2009, 129:954-963. 10.1038/jid.2008.329.
38. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36. 10.1093/carcin/bgp220.
39. Srivastava S., Mishra R.K., Dhawan J. Regulation of cellular chromatin state: insights from quiescence and differentiation. Organogenesis 2010, 6:37-47.
40. Takeuchi T., Adachi Y., Sonobe H., Furihata M., Ohtsuki Y. A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion. Oncogene 2006, 25:7059-7069. 10.1038/sj.onc.1209688.
41. Teerlink C., Farnham J., Allen-Brady K., Camp N.J., Thomas A., Leachman S., Cannon-Albright L. A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum. Genet. 2012, 131:77-85. 10.1007/s00439-011-1048-z.
42. Teschendorff A.E., Menon U., Gentry-Maharaj A., Ramus S.J., Gayther S.a, Apostolidou S., Jones A., Lechner M., Beck S., Jacobs I.J., Widschwendter M. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 2009, 4:e8274. 10.1371/journal.pone.0008274.
43. Touleimat N., Tost J. Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. Epigenomics 2012, 4:325-341. 10.2217/epi.12.21.
44. Tsao H., Chin L., Garraway L.a, Fisher D.E. Melanoma: from mutations to medicine. Genes Dev. 2012, 26:1131-1155. 10.1101/gad.191999.112.
45. Udayakumar D., Mahato B., Gabree M., Tsao H. Genetic determinants of cutaneous melanoma predisposition. Semin. Cutan. Med. Surg. 2010, 29:190-195. 10.1016/j.sder.2010.06.002.
46. Van Doorn R., Zoutman W.H., Gruis N.a Absence of germline epimutation of the CDKN2A gene in familial melanoma. J. Invest. Dermatol. 2009, 129:781-784. 10.1038/jid.2008.287.
47. Walker G.J., Indsto J.O., Sood R., Faruque M.U., Hu P., Pollock P.M., Duray P., Holland E.a, Brown K., Kefford R.F., Trent J.M., Mann G.J., Hayward N.K. Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. Gene Chromosome Cancer 2004, 41:56-64. 10.1002/gcc.20056.
48. Wang L., Aakre J.A., Jiang R., Marks R.S., Wu Y., Chen J., Thibodeau S.N., Pankratz V.S., Yang P. Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. J. Thorac. Oncol. 2010, 5:778-785. 10.1097/JTO.0b013e3181d6e0b3.
49. Ward K.a, Lazovich D., Hordinsky M.K. Germline melanoma susceptibility and prognostic genes: a review of the literature. J. Am. Acad. Dermatol. 2012, 67:1055-1067. 10.1016/j.jaad.2012.02.042.
50. Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S., Stemke-Hale K., Davies M.a, Gershenwald J.E., Robinson W., Robinson S., Rosenberg S.a, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 2011, 43:442-446. 10.1038/ng.810.
51. Woo H.D., Kim J. Global DNA hypomethylation in peripheral blood leukocytes as a biomarker for cancer risk: a meta-analysis. PLoS One 2012, 7:e34615. 10.1371/journal.pone.0034615.